Equities

Alkem Laboratories Ltd

Alkem Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,583.35
  • Today's Change-23.40 / -0.42%
  • Shares traded108.56k
  • 1 Year change+22.98%
  • Beta0.6204
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments42,69711,43213,130
Total Receivables, Net30,64128,65325,612
Total Inventory27,83427,28930,630
Prepaid expenses499444564
Other current assets, total2,44419,47914,417
Total current assets104,11687,29784,354
Property, plant & equipment, net25,57025,13527,659
Goodwill, net4,1674,1324,031
Intangibles, net576794722
Long term investments4,0515,2498,803
Note receivable - long term1,9731,4981,686
Other long term assets1454041
Total assets155,749137,566140,692
LIABILITIES
Accounts payable17,48111,65011,734
Accrued expenses6,1036,0045,764
Notes payable/short-term debt11,74013,07225,707
Current portion long-term debt/capital leases152192216
Other current liabilities, total4,4706,1544,633
Total current liabilities39,94637,07248,053
Total long term debt2,293703759
Total debt14,18413,96726,682
Deferred income tax------
Minority interest4,0233,8972,094
Other liabilities, total6,3675,4423,407
Total liabilities52,62847,11354,313
SHAREHOLDERS EQUITY
Common stock239239239
Additional paid-in capital------
Retained earnings (accumulated deficit)101,00988,73785,817
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1,6771,471317
Total equity103,12190,45386,379
Total liabilities & shareholders' equity155,749137,566140,692
Total common shares outstanding120120120
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.